•
•
•
•
•
•
•
•
Country
US
Industry
Health Care
Market Cap
Small Cap
Num. Employees
226
IPO Date
Feb 3, 2016
Country
US
Industry
Health Care
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 226 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cas12a), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The company is engaged in the development of in vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, EDIT-301, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta-thalassemia (TDT).
Sources
Mentions
Mentions of this stock across all news source scraped in the past 30 days
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Fintel
92.8%
Yahoo
5.6%
SeekingAlpha
0.8%
Others
0.8%
Baird lowered Baird's price target on Editas Medicine (EDIT) to $8 from $10 and keeps an Outperform rating on the shares.
Recent Mentions
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
News Sentiment
Sentiment
Composite sentiment (positive vs. negative language) expressed across news sources mentioning this stock
Today
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Very Bullish
+31.77% more bullish
compared to last week
Related Stocks
Related Stocks
Stocks being mentioned with EDIT